drugset / Trial / NCT03393689

RGD PET/MRI in Sporadic Vestibular Schwannoma

NCT03393689 ↗

Phase 2 Unknown 40 enrolled Rigshospitalet, Denmark
NaSingle-groupOpen-labelDiagnostic

Summary

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with sporadic Vestibuarl Schwannomas.

Timeline

Start
2018-01-02
Primary completion
2021-01-02
Completion
2021-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject [68Ga]Ga-NODAGA-E[c(RGDyK)]2 Diagnostic / imaging agent 200 mbq Intravenous

Indications